As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 13.03% on an annualized basis producing an average annual return of 21.14%. Currently, Vertex Pharmaceuticals has ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex reported revenues of $2.65 billion in the last reported quarter, representing a year-over-year change of +6.1%. EPS of -$12.83 for the same period compares with $3.89 a year ago.

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time ...

Vertex reported revenues of $2.65 billion in the last reported quarter, representing a year-over-year change of +6.1%. EPS of -$12.83 for the same period compares with $3.89 a year ago.

Except for the last several days, the past 12 months have been pretty good for stocks across the board and especially successful for Vertex Pharmaceuticals (NASDAQ: VRTX). Shares of the biotech ...

LONDON, August 07, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.28% higher to $481.24 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX ...

Dividend stocks offer long-term investors unique benefits.

View Vertex Pharmaceuticals Incorporated (VRTX) current and estimated P/E ratio data provided by Seeking Alpha.